Announcement PDF Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Neurizon® AGM Date and Director Nominations Closing Date for AGM 5 August 2025 – Melbourne, Australia: Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, advises that its next Annual General Meeting (“AGM”) will be held on Tuesday, 30 September 2025. An election of directors will be held at this AGM pursuant to ASX Listing Rule 14.5. Details of the Director’s to be elected will be included in the forthcoming Notice of AGM. In accordance with ASX Listing Rule 3.13.1 and rule 7.2(f)(ii) of the Company’s Constitution, the Company advises that the Closing Date for receipt of nominations for the position of Director is Tuesday, 12 August 2025. Any nominations must be received in writing no later than 5.00pm (Melbourne time) on Tuesday, 12 August 2025 at the Company’s registered office. The Company notes that the deadline for nominations for the position of Director is separate to voting on Director elections. Details of the Director’s to be elected will be provided in the Company Notice of AGM in due course. -ENDSThis announcement has been authorized for release by the Board of Neurizon Therapeutics Limited. For further information, please contact: Dr. Michael Thurn Managing Director and Chief Execufive Officer Neurizon Therapeufics Limited enquiries@neurizon.com +61 (3) 9692 7222 Lidija Damjanovic Head of Markefing and Corporate Affairs Neurizon Therapeufics Limited lidija@neurizon.com +61 (0) 425 700 504 Released through: Henry Jordan, Six Degrees Investor Relations, +61 (0) 431 271 538 About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. Neurizon Investor Hub We encourage you to ufilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This plafform offers an opportunity to submit quesfions, share comments, and view video summaries of key announcements. To access Neurizon Investor Hub please scan the QR code or visit hftps://investorhub.neurizon.com Neurizon® is a registered trademark of Neurizon Therapeutics Limited Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222